# Effect of SARSCoV2 (COVID-19) Vaccination in Type 1 Diabetes (CoVaxT1D)

> **NCT04905823** · — · COMPLETED · sponsor: **Paolo Fiorina, MD** · enrollment: 600 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DIAGNOSTIC_TEST:** blood test

## Key facts

- **NCT ID:** NCT04905823
- **Lead sponsor:** Paolo Fiorina, MD
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-31
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-06-30
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2023-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04905823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04905823, "Effect of SARSCoV2 (COVID-19) Vaccination in Type 1 Diabetes (CoVaxT1D)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04905823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*